Which startups have raised the most funding in the longevity market?
Download our beautiful pitch about the longevity market

In our longevity market deck, you will find everything you need to understand the market
The longevity market has attracted over $13 billion in venture funding, with startups working on everything from cellular reprogramming to consumer health diagnostics.
Below is a ranked list of the top funded longevity startups, built from verified public sources and updated every month to keep the data fresh.
Whether you are an investor scouting deals, a founder benchmarking your raise, or a researcher tracking where capital flows in aging science, this page is your reference.
And if you want to better understand this new industry, you can download our pitch covering the longevity market.
A quick summary table
| Metric | Value |
|---|---|
| Most funded longevity startup | Altos Labs ($3.0B) |
| Second most funded longevity startup | Oura / Retro Biosciences (tied at $1.2B) |
| Largest single longevity funding round | Retro Biosciences ($1.0B, Series A) |
| Median funding across longevity startups | ~$24M |
| Share of funding captured by the top 10 | ~67% |
| Median time since last round | ~17 months |
| Longevity startups that raised in the last 12 months | 35 out of 94 |
| Total capital deployed in longevity startups | ~$13.1B |
| Longevity startups with IPO or acquisition exit | 8 (4 IPOs, 4 acquired) |
| Most active longevity investor by portfolio count | Khosla Ventures (6+ companies) |

In our longevity market deck, we show you long-term trends so you can make better decisions
Top startups in the longevity market ranked by total funding raised
Here is an updated table that ranks the top startups in the longevity market based on the total amount of funding they have raised to date.
The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup's current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).
If you're interested in knowing how much these startups are worth, you can check our list of the top startups in the longevity market ranked by valuation.
| # | Startup | What They Do | Total Raised ($) | Total Rounds | Last Round Date | Last Round Amount ($) | Last Round Type | Key Investors | Current Stage | Confidence |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Altos Labs | Cellular rejuvenation therapeutics | $3.0B | 1 | January 2022 | $3.0B | Initial financing | ARCH Venture Partners, Jeff Bezos, Yuri Milner | Active | Strong |
| 2 | Oura | Smart health-tracking ring platform | $1.2B | 9 | October 2025 | $900M | Series E | Fidelity, ICONIQ, Whale Rock | Active | Partial |
| 3 | Retro Biosciences | Longevity therapeutics for age reversal | $1.2B | 2 | January 2025 | $1.0B | Series A | Sam Altman | Active | Strong |
| 4 | BioSplice Therapeutics | Alternative-splicing therapeutics for diseases | $778M | 3 | April 2021 | $120M | Equity financing | Eventide Asset Management, aMoon, SymBiosis II | Active | Strong |
| 5 | Insilico Medicine | AI-driven drug discovery platform | $688M | 6 | December 2025 | $293M | IPO | Warburg Pincus, Qiming Venture Partners | IPO | Strong |
| 6 | BioAge Labs | Aging-targeted obesity therapeutics | $491M | 5 | September 2024 | $198M | IPO | Sofinnova, RA Capital, Andreessen Horowitz | IPO | Strong |
| 7 | Celularity | Placenta-derived cell therapies | $396M | 4 | October 2025 | $2M | Private Placement | Celgene, Starr Insurance, Dragasac Limited | IPO | Partial |
| 8 | Human Longevity | Precision longevity clinics and diagnostics | $380M | 5 | August 2024 | $40M | Series B | TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners | Active | Partial |
| 9 | Function Health | Preventive diagnostics and health platform | $351M | 2 | November 2025 | $298M | Series B | Redpoint Ventures, Andreessen Horowitz, Aglaé Ventures | Active | Strong |
| 10 | Neko Health | Preventive body-scan health centers | $325M | 2 | January 2025 | $260M | Series B | Lightspeed Venture Partners, General Catalyst, Lakestar | Active | Full |
| 11 | Juvenescence | Longevity drug development platform | $283M | 5 | May 2025 | $76M | Series B-1 | M42, Grok Ventures, IPGL | Active | Partial |
| 12 | NewLimit | Epigenetic reprogramming medicines | $280M | 3 | May 2025 | $130M | Series B | Kleiner Perkins, Khosla Ventures, NFDG | Active | Full |
| 13 | Viome Life Sciences | Microbiome diagnostics and nutrition | $243M | 6 | September 2024 | $25M | Series D | Khosla Ventures, Bold Capital, WRG Ventures | Active | Full |
| 14 | Loyal | Longevity drugs for dogs | $205M | 5 | February 2026 | $100M | Series C | age1, Baillie Gifford | Active | Partial |
| 15 | Unity Biotechnology | Senolytic drugs for aging diseases | $200M | 4 | March 2018 | $55M | Series C | EcoR1 Capital, 6 Dimensions Capital, ARCH Venture Partners | Shutdown | Full |
| 16 | Cambrian Bio | Builds healthspan therapeutics platform | $188M | 4 | June 2023 | $23M | Later-stage private round | Anthos Capital, Apeiron Investment Group | Active | Partial |
| 17 | resTORbio | mTOR inhibitors for aging diseases | $163M | 3 | January 2018 | $98M | IPO | PureTech Health, OrbiMed | Acquired | Full |
| 18 | Alzheon | Alzheimer's oral therapeutics developer | $160M | 3 | June 2024 | $100M | Series E | Alerce Medical Technology Partners | Active | Partial |
| 19 | Life Biosciences | Aging-related disease therapeutics | $157M | 3 | January 2022 | $82M | Series C | Alpha Wave Ventures | Active | Strong |
| 20 | SciNeuro Pharmaceuticals | Neurodegenerative disease therapeutics | $153M | 2 | December 2025 | $53M | Equity Financing | LAV, ARCH Venture Partners | Active | Full |
| 21 | Aeovian Pharmaceuticals | Selective mTORC1 small molecules | $142M | 3 | December 2025 | $55M | Series B | Luma Group, CTI Life Sciences Fund, Foresite Capital | Active | Full |
| 22 | Nura Bio | Neuroprotective small-molecule biotech | $141M | 2 | September 2024 | $68M | Series A extension | The Column Group, Samsara BioCapital, Sanofi Ventures | Active | Full |
| 23 | Fountain Life | Longevity clinics and diagnostics | $113M | 3 | August 2025 | $18M | Series B | EOS Ventures, Todd Wanek, B.K. Modi | Active | Partial |
| 24 | Nuritas | AI-discovered bioactive peptide ingredients | $110M | 4 | December 2024 | $42M | Series C | M&G Investments, McWin Capital Partners, Grosvenor | Active | Full |
| 25 | L-Nutra | Longevity nutrition and fasting products | $84M | 3 | January 2026 | $37M | Series D | Mubadala, Brentwood Associates, Stéphane Bancel | Active | Partial |
| 26 | Corsera Health | Cardiovascular prediction and prevention biotech | $80M | 1 | January 2026 | $80M | Series A | Forbion, Population Health Partners, John Maraganore | Active | Full |
| 27 | Rejuveron Life Sciences | Longevity therapeutics platform | $76M | 2 | September 2023 | $75M | Series B | Catalio Capital, Apeiron Investment Group, Mubadala Capital | Active | Partial |
| 28 | Timeline | Longevity supplements and skin health | $75M | 2 | January 2024 | $66M | Series D | BOLD (L'Oréal), Nestlé | Active | Strong |
| 29 | CohBar | Mitochondria-based therapeutics for aging | $65M | 6 | November 2021 | $15M | Public offering | Public-market investors | Shutdown | Partial |
| 30 | Illimis Therapeutics | Neuroinflammation fusion-protein therapeutics | $64M | 3 | July 2025 | $42M | Series B | DSC Investment, Woori Venture Partners, Korea Development Bank | Active | Partial |
| 31 | Elevian | Regenerative medicines for aging | $61M | 3 | September 2021 | $40M | Series A | Prime Movers Lab, Bold Capital Partners, Leslie Ventures | Active | Full |
| 32 | Blueprint | Consumer longevity products platform | $60M | 1 | October 2025 | $60M | Angel / Venture Round | Naval Ravikant, Balaji Srinivasan, Winklevoss brothers | Active | Partial |
| 33 | Gordian Biotechnology | In vivo screening for aging therapies | $60M | 1 | April 2025 | Undisclosed | Venture equity | The Longevity Fund, Founders Fund, Gigafund | Active | Low |
| 34 | Elysium Health | Consumer longevity health products | $60M | 2 | December 2019 | $40M | Series C | GISEV Family Office, Mayo Clinic Ventures, General Catalyst | Active | Low |
| 35 | Liom | Non-invasive biomarker wearable | $59M | 3 | December 2025 | $16M | Series A extension | Ornament Health, Geberit, Red Bull Ventures | Active | Partial |
| 36 | Neurable | Brain-computer interface consumer tech | $56M | 4 | December 2025 | $35M | Series A | Pace Ventures, M Ventures, Ultratech Capital Partners | Active | Strong |
| 37 | Biograph | Preventive longevity diagnostics clinics | $54M | 2 | February 2025 | Undisclosed | Seed VC | Vy Capital, Human Capital, WndrCo | Active | Low |
| 38 | Rubedo Life Sciences | Senolytic therapies for aging diseases | $52M | 2 | April 2024 | $40M | Series A | Khosla Ventures, Ahren Innovation Capital, LongeVC | Active | Full |
| 39 | Arda Therapeutics | Targeted cell depletion therapies | $43M | 1 | October 2024 | $43M | Series A | a16z, Two Sigma Ventures, GV | Active | Full |
| 40 | Alkahest | Plasma-based aging therapeutics | $41M | 2 | March 2015 | $38M | Series A | Grifols | Acquired | Strong |
| 41 | Cellular Origins | Cell therapy manufacturing automation | $40M | 1 | December 2025 | $40M | Series A | Johnson & Johnson Innovation, Highland Europe, BGF | Active | Full |
| 42 | LyGenesis | Organ regeneration using lymph nodes | $40M | 3 | October 2024 | $18M | Series A extension | Prime Movers Lab, Juvenescence | Active | Partial |
| 43 | Neuraly | Neurodegenerative disease therapeutics | $36M | 2 | July 2018 | $36M | Series A | D&D Pharmatech, Smilegate Investment, InterVest | Active | Partial |
| 44 | Jocasta Neuroscience | Klotho therapies for cognition | $35M | 1 | August 2025 | $35M | Series A | True Ventures, Moore Strategic Ventures, SC8 Investments | Active | Full |
| 45 | Amplifier Therapeutics | AMPK drugs for aging diseases | $33M | 1 | October 2023 | $33M | Series A | Cambrian Bio, RA Capital, Future Ventures | Active | Strong |
| 46 | Turn Biotechnologies | mRNA epigenetic reprogramming therapies | $29M | 2 | September 2023 | $29M | Series A | Khosla Ventures, Formic Ventures, Shanda Group | Active | Low |
| 47 | Oisin Biotechnologies | Genetic medicines for age-related disease | $25M | 3 | July 2024 | $15M | Series A | AbbVie Ventures, Kizoo, Qiming Venture Partners USA | Active | Partial |
| 48 | Cyclarity Therapeutics | Oxysterol-targeting age-related therapeutics | $24M | 4 | December 2024 | $6M | Series A tranche 1 | Not fully disclosed | Active | Full |
| 49 | MindImmune Therapeutics | Neuroinflammation drugs for Alzheimer's | $24M | 4 | November 2025 | $10M | Series A extension | Dolby Family Ventures, Pfizer Ventures, Gates Frontier | Active | Partial |
| 50 | Tolerance Bio | Thymus-based immune therapies | $20M | 2 | December 2024 | $3M | Seed extension | Pacific 8 Ventures, Columbus Venture Partners, Criteria Bio Ventures | Active | Full |
| 51 | Junevity | siRNA cell-reprogramming therapeutics | $20M | 2 | December 2025 | $10M | Seed Extension | Goldcrest Capital, Godfrey Capital | Active | Full |
| 52 | Modulo Bio | Neuroimmune drugs for neurodegeneration | $19M | 3 | March 2025 | $5M | Strategic investment | ADDF, Initialized Capital, Cantos | Active | Strong |
| 53 | Shift Bioscience | AI-driven cell rejuvenation discovery | $18M | 1 | October 2024 | $16M | Seed | BGF, F-Prime Capital, Kindred Capital | Active | Low |
| 54 | Longevica | Longevity therapeutics and supplements | $16M | 2 | November 2021 | $3M | Venture round | Xploration Capital | Acquired | Partial |
| 55 | Generation Lab | Biological age diagnostics | $15M | 2 | October 2025 | $11M | Seed | Accel, Samsung Next, Zone2 | Active | Partial |
| 56 | Booster Therapeutics | Proteasome activator medicines | $15M | 1 | October 2024 | $15M | Seed | Apollo Health Ventures, Novo Holdings | Active | Full |
| 57 | Rejuvenate Bio | Gene therapies for age-related disease | $15M | 1 | April 2021 | $15M | Series A | Kendall Capital Partners, VCapital, Digitalis Ventures | Active | Strong |
| 58 | Grey Matter Neurosciences | Ultrasound therapies for brain aging | $14M | 1 | January 2025 | $14M | Seed | Wittington Innovation Fund, TIAP, Ontario Brain Institute | Active | Full |
| 59 | Edifice Health | Inflammation and immune-age diagnostics | $14M | 1 | April 2021 | $14M | Series A | Leaps by Bayer, Paladin Capital, Vertical Venture Partners | Active | Strong |
| 60 | Morphoceuticals | Bioelectric regenerative medicine platform | $13M | 2 | September 2024 | $4M | Seed | Prime Movers Lab, Juvenescence | Active | Strong |
| 61 | Radar Therapeutics | RNA-sensing programmable medicines | $13M | 1 | May 2024 | $13M | Seed | NFX Bio, Eli Lilly, Biovision Ventures | Active | Full |
| 62 | Amphix Bio | Peptide therapeutics for regeneration | $13M | 1 | December 2025 | $13M | Seed | Not publicly disclosed | Active | Partial |
| 63 | MitoRx Therapeutics | Mitochondrial-targeted obesity therapeutics | $12M | 3 | November 2025 | $7M | Pre-Series A | Oshen Holdings, Wren Capital, UKI2S | Active | Strong |
| 64 | Circulate Health | Therapeutic plasma exchange longevity | $12M | 1 | July 2025 | $12M | Seed | Khosla Ventures, Seaside Ventures, CSC Ventures | Active | Full |
| 65 | Everlab | AI preventive longevity healthcare | $12M | 2 | July 2025 | $10M | Seed | Left Lane Capital, AfterWork Ventures | Active | Full |
| 66 | Acorn Biolabs | Cell preservation for regenerative medicine | $12M | 3 | May 2024 | $8M | Series A | Merz Aesthetics, TELUS Global Ventures, MDE Investments | Active | Strong |
| 67 | Epiterna | Longevity therapeutics for pets and humans | $11M | 1 | August 2023 | $11M | Seed | Prima Materia | Active | Full |
| 68 | Rejuvenation Technologies | mRNA telomere-lengthening therapeutics | $11M | 1 | September 2023 | $11M | Seed | Khosla Ventures, Shanda Ventures, Asymmetry Ventures | Active | Full |
| 69 | Cirrus Therapeutics | Ocular gene and cell therapies | $11M | 1 | October 2025 | $11M | Seed | ClavystBio, Polaris Partners, SEEDS | Active | Full |
| 70 | Vasa Therapeutics | Cardiovascular aging therapeutics | $11M | 2 | March 2024 | $5M | Seed extension | Orphinic Scientific, i&i Biotech Fund I SCSp | Active | Strong |
| 71 | Repair Biotechnologies | Cholesterol-clearing aging therapeutics | $11M | 3 | June 2023 | $9M | Series A | Undisclosed | Active | Partial |
| 72 | Tally Health | Consumer longevity testing and supplements | $10M | 1 | April 2023 | $10M | Seed | Forerunner Ventures, L Catterton, G9 Ventures | Active | Full |
| 73 | NaNotics | Subtractive nanoparticles for disease | $10M | 2 | October 2023 | Undisclosed | Series A | LifeSpan Vision Ventures | Active | Low |
| 74 | clock.bio | Rejuvenation biology drug discovery | $9M | 2 | October 2024 | $5M | Seed | LocalGlobe, BlueYard Capital, Onsight Ventures | Active | Partial |
| 75 | Biopeak | AI-driven longevity clinics | $8M | 3 | January 2026 | $3M | Follow-on venture round | NKSquared, Prashanth Prakash, Claypond Capital | Active | Partial |
| 76 | Gero | AI aging drug discovery | $8M | 3 | October 2023 | $6M | Series A extension | Melnichek Investments, Bulba Ventures | Active | Partial |
| 77 | SENISCA | RNA-based senotherapeutics | $7M | 2 | March 2024 | $5M | Seed | Emerging Longevity Ventures, QantX, Lifespan Vision Ventures | Active | Strong |
| 78 | Thymmune Therapeutics | Thymic cell immune therapies | $7M | 1 | March 2023 | $7M | Seed | Pillar VC, NYBC Ventures, George Church | Active | Strong |
| 79 | Cyclana Bio | Women's health tissue therapeutics | $7M | 1 | October 2025 | $7M | Pre-Seed | NFX, Eka Ventures, Cocoa VC | Active | Full |
| 80 | Matter Bio | Genome integrity longevity therapeutics | $7M | 2 | May 2024 | $7M | Seed | LifeSpan Vision Ventures, quadraScope Ventures | Active | Partial |
| 81 | Genflow Biosciences | Gene therapies for longevity | $6M | 3 | March 2025 | $1M | Post-IPO equity investment | Premier Miton | IPO | Strong |
| 82 | Tomorrow Bio | Human cryonics and biostasis | $6M | 1 | May 2025 | $6M | Seed | Blast.Club, Truventuro | Active | Strong |
| 83 | Biolytica | AI longevity data platform | $6M | 1 | May 2023 | $6M | Seed | Maximon | Active | Full |
| 84 | Deciduous Therapeutics | Senescent-cell clearing immunotherapies | $6M | 5 | October 2023 | Undisclosed | Venture equity | LifeSpan Vision Ventures | Active | Low |
| 85 | GlycanAge | Glycan-based biological age testing | $4M | 1 | February 2024 | $4M | Seed | LAUNCHub Ventures, Kadmos Capital | Active | Full |
| 86 | NADMED | NAD metabolite diagnostic testing | $4M | 2 | August 2024 | $4M | Series A | Nordic Science Investments, Voima Ventures, University of Helsinki Funds | Active | Full |
| 87 | AgelessRx | Longevity telehealth prescriptions platform | $4M | 2 | November 2022 | Undisclosed | Undisclosed equity round | Joshua Rosenthal, Pareto Holdings | Active | Partial |
| 88 | Mito Health | AI preventive health platform | $4M | 3 | March 2025 | $2M | Seed | Y Combinator, Capital X, XA Network | Active | Partial |
| 89 | NOVOS | Longevity nutraceuticals and testing | $3M | 2 | March 2026 | Undisclosed | Strategic minority investment | Unilever Ventures | Active | Partial |
| 90 | Bionic Health | AI-powered preventive care clinic | $3M | 1 | March 2023 | $3M | Seed | IDEA Fund Partners, Studio VC, Alumni Ventures | Acquired | Full |
| 91 | Decode Age | Longevity tests and supplements | $2M | 3 | December 2025 | $2M | Pre-Series A | Krishna Prasad Chigurupati, IVY Growth Associates | Active | Low |
| 92 | ImmuneAGE Bio | Immune-system rejuvenation platform | $2M | 1 | July 2024 | $2M | Seed | Balaji Srinivasan, Thomas Ebeling | Active | Partial |
| 93 | Leucadia Therapeutics | Alzheimer's device-based therapy | $2M | 1 | 2017 | $2M | Seed | Methuselah Fund, Bioverge Ventures, Wasabi Ventures | Active | Low |
| 94 | LinkGevity | Anti-necrotic longevity drug discovery | <$1M | 1 | January 2025 | <$1M | Accelerator / Pre-Seed | KQ Labs, Francis Crick Institute | Active | Partial |

In our longevity market deck, we will give you useful market maps and grids
Key funding trends in the longevity market
Insights
- Altos Labs' $3.0B single round exceeds the combined funding of Retro Biosciences and BioSplice Therapeutics ($2.0B together), making cellular reprogramming the most capital-intensive bet in longevity therapeutics.
- Function Health's $298M Series B is the largest disclosed venture round among private longevity startups, a signal that investors see consumer-scale potential in preventive lab-testing platforms beyond traditional biotech drug pipelines.
- Khosla Ventures appears in at least six longevity portfolios (including Circulate Health, Rubedo Life Sciences, Rejuvenation Technologies, Viome, and NewLimit), making the firm arguably the most prolific dedicated longevity market investor.
- Consumer-facing longevity platforms (Neko Health, Function Health, Viome, Tally Health, Acorn Biolabs) collectively raised over $700M, showing that longevity funding now extends well beyond drug pipelines into diagnostics, wearables, and supplements.
- Retro Biosciences ($1.2B) and NewLimit ($280M), backed respectively by Sam Altman and Coinbase co-founder Brian Armstrong, together account for $1.5B and illustrate how tech-founder conviction capital is reshaping the scale of longevity funding.
- Unity Biotechnology raised $200M through Series C before shutting down, a quantitative reminder that substantial early funding does not guarantee clinical or commercial success in the senolytics space.
- Booster Therapeutics ($15M seed from Apollo Health Ventures and Novo Holdings) and Radar Therapeutics ($13M seed with Eli Lilly participation) show large pharma-adjacent investors actively seeding early-stage longevity platforms at competitive round sizes.
- Corsera Health raised $80M in a single Series A (the largest disclosed Series A for cardiovascular aging), suggesting that cardiometabolic longevity is now attracting conviction-sized first rounds from specialist biotech investors.
- Cellular Origins' $40M Series A for cell therapy manufacturing automation, backed by J&J Innovation, signals that longevity market investors value manufacturing infrastructure alongside therapeutic pipelines.

In our longevity market deck, we have collected signals proving this market is hot right now
A few word about our methodology
As you can see, we built a database that ranks startups in the longevity market based on their total cumulative fundraising. To create this ranking, we reviewed many sources and cross-checked information across multiple places.
Whenever possible, we prioritized official company communications, since they are the most reliable source for funding amounts. When those were not available, we relied on reputable industry sources such as TechCrunch, Crunchbase, Financial Times or Forbes (to name a few).
We excluded random blogs, unverified websites, and any sources that could not be validated.
When funding rounds were announced in other currencies such as euros, Swiss francs, Singapore dollars, Australian dollars, or rupees, we converted them into approximate USD equivalents for consistency.
Sometimes different sources report slightly different numbers, or the exact round size is not fully disclosed. In those cases, we flag the uncertainty and assign a confidence label to each startup, visible in the last column.
Here is what they mean.
Full confidence: The longevity startup's equity fundraising history can be reconstructed completely from public sources. The rounds, dates, amounts, and key investors are clearly identified, with no meaningful gaps.
Strong confidence: The fundraising history is largely complete and reliable. There may be a small missing detail, such as incomplete investor information or a minor round with limited data, but the overall record is clear.
Partial confidence: The main fundraising rounds can be identified, but the record is incomplete or somewhat mixed. Some rounds may be missing or certain funding events may be difficult to separate clearly.
Low confidence: Public information is too limited, inconsistent, or ambiguous to reliably reconstruct the company's equity fundraising history.
When the confidence level is too low, we take a conservative approach and exclude the company from the ranking. We don't want to include data that cannot be reliably verified.
This reflects how we conduct all our research, including the work behind our report covering the longevity market.
In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.
If you want the full detail on a specific calculation, feel free to contact us and we will gladly explain.
Finally, know that we update the dataset once per month, so come back here if you need fresh information.

In our longevity market deck, we identify repeatable patterns you can use if you’re building in this market
Related blog posts
- The most recent news in the longevity market
- The most recent funding news in the longevity market
- The latest developments shaping the longevity market
- The evolution of funding activity in the longevity market
- The main fundraising trends in the longevity market
Who is the author of this content?
NEW MARKET PITCH TEAM
We track new markets so founders and investors can move fasterWe build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.
How we created this content 🔎📝
At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.
So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.
Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.